Geldanamycin (NSC 122750) Clinical Trials

Size	Price	Qty
5mg	USD 170
50mg	USD 670

Clinical Trials

Multiple Phase I and Phase II clinical trials have evaluated geldanamycin derivatives across various malignancies, including adult and pediatric solid tumors, non-Hodgkin lymphoma, prostate cancer, melanoma, renal cell carcinoma, and leukemias. Focused on pharmacokinetic safety, dose escalation, and preliminary efficacy, these studies have overall recruitment statuses listed as completed or terminated. Prominent sponsors driving this research include the National Cancer Institute, Cancer Research UK, Memorial Sloan Kettering Cancer Center, and Biogen.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00019708	TERMINATED	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific	National Cancer Institute (NCI)	1999-06	PHASE1
NCT00119236	COMPLETED	Unspecified Adult Solid Tumor, Protocol Specific	National Cancer Institute (NCI)	2005-05	PHASE1
NCT00058253	COMPLETED	Recurrent Prostate Cancer; Stage IV Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific	National Cancer Institute (NCI)	2003-02	PHASE1
NCT00093821	COMPLETED	Childhood Chronic Myelogenous Leukemia; Childhood Desmoplastic Small Round Cell Tumor; Disseminated Neuroblastoma; Metastatic Childhood Soft Tissue Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Metastatic Osteosarcoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma	National Cancer Institute (NCI)	2004-09	PHASE1
NCT00087386	TERMINATED	Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma	National Cancer Institute (NCI)	2004-06	PHASE2
NCT00004065	COMPLETED	Bladder Cancer; Breast Cancer; Colorectal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific	Memorial Sloan Kettering Cancer Center	1999-07	PHASE1
NCT00003969	Completed	Unspecified Adult Solid Tumor Protocol Specific	Cancer Research UK\|National Cancer Institute (NCI)	1998-08	Phase 1
NCT00093405	COMPLETED	Kidney Cancer	Memorial Sloan Kettering Cancer Center	2004-08	PHASE2
NCT00003969	COMPLETED	Unspecified Adult Solid Tumor, Protocol Specific	Cancer Research UK	1998-08	PHASE1
NCT00319930	TERMINATED	Chronic Lymphocytic Leukemia	Biogen	2005-05	PHASE1

(data from https://clinicaltrials.gov, updated on 2013-12-16)

Check the Geldanamycin (NSC 122750) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Geldanamycin directly binds to Heat Shock Protein 90 (Hsp90), thereby disrupting its chaperone function and destabilizing key oncogenic client proteins such as v-Src, Bcr-Abl, and mutant p53. This inhibition triggers proteasomal degradation of these essential signaling proteins to suppress tumor cell survival, supporting its investigation in clinical trials targeting advanced solid tumors, lymphomas, and melanoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).